Institute of Medicine, Department of Family Medicine, Chung-Shan Medical University, Taichung, Taiwan.
Histopathology. 2010 Sep;57(3):384-94. doi: 10.1111/j.1365-2559.2010.03647.x.
Prostatic cancer is resistant to chemotherapy. Expression of aldo-keto reductase 1C (AKR1C) has been associated with drug resistance and disease progression in several cancers. The aim was to investigate the relationship between AKR1C expression and disease progression in prostatic cancer.
From January 1996 to December 2005, 86 pathological samples were collected from patients with prostatic cancer. A tissue microarray containing 31 prostatic cancers from American patients was used for comparison between Chinese and American patients. Using immunohistochemistry, aldo-keto reductase family 1, member C2 (AKR1C2) expression was assessed in tissue sections. The AKR1C2 was determined by two-dimensional immunoblotting and DNA sequencing of reverse transcriptase-polymerase chain reaction products. The relationship between AKR1C2 expression and clinicopathological variables was statistically analysed. In vitro, the association between AKR1C2 expression and drug resistance was investigated in androgen-sensitive and androgen-insensitive prostatic cancer cells. DNA sequencing and two-dimensional immunoblotting showed that prostatic cancer expressed AKR1C2. It was overexpressed in 77 of 86 (89.5%) Chinese and in 28 of 31 (90.3%) American samples. No difference was found in AKR1C2 expression between Chinese and American prostatic cancer patients. In vitro, increased expression of AKR1C2 and prostaglandin F2α correlated with cytoprotection against anticancer drugs and lycopene.
Overexpression of AKR1C2 is associated with disease progression in prostatic cancer.
前列腺癌对化疗有抗性。醛酮还原酶 1C（AKR1C）的表达与几种癌症中的耐药性和疾病进展有关。本研究旨在探讨 AKR1C 表达与前列腺癌疾病进展之间的关系。
1996 年 1 月至 2005 年 12 月，从前列腺癌患者中收集了 86 个病理样本。使用包含 31 个美国患者前列腺癌的组织微阵列用于中美患者之间的比较。使用免疫组织化学方法，评估组织切片中醛酮还原酶家族 1，成员 C2（AKR1C2）的表达。通过二维免疫印迹和逆转录聚合酶链反应产物的 DNA 测序来确定 AKR1C2。统计分析 AKR1C2 表达与临床病理变量之间的关系。在体外，研究了 AKR1C2 表达与雄激素敏感和雄激素不敏感前列腺癌细胞耐药性之间的关系。DNA 测序和二维免疫印迹表明前列腺癌表达 AKR1C2。在中国患者的 86 个样本中，有 77 个（89.5%）过度表达，在美国患者的 31 个样本中，有 28 个（90.3%）过度表达。中国和美国前列腺癌患者之间的 AKR1C2 表达没有差异。在体外，AKR1C2 和前列腺素 F2α 的表达增加与抗癌药物和番茄红素的细胞保护作用相关。
AKR1C2 的过度表达与前列腺癌的疾病进展有关。
